Mitral atresia
MY-truhl uh-TREE-zhuh
Also known as: Congenital mitral atresia, Atresia of the left atrioventricular valve
At a Glance
What is Mitral atresia?
Mitral atresia is a rare congenital heart defect where the mitral valve, which controls blood flow between the left atrium and left ventricle, is absent. This condition affects the cardiovascular system, leading to improper blood circulation. It is caused by developmental issues during fetal growth that prevent the mitral valve from forming. Over time, this can lead to complications such as heart failure or pulmonary hypertension. Early symptoms may include difficulty breathing, poor feeding, and cyanosis, while later symptoms can involve fatigue and growth delays. Early diagnosis is crucial to manage the condition and prevent severe complications. The condition can be stressful for families due to the need for frequent medical care and potential surgeries. Prognosis varies depending on the severity and associated heart defects, but with treatment, some individuals can lead relatively normal lives. Daily life for affected individuals often involves regular medical check-ups and possibly medications or surgical interventions. Support from healthcare providers and family is essential to manage the condition effectively. Lifestyle adjustments may be necessary to accommodate the child's health needs. Ongoing research aims to improve treatment options and outcomes for those affected by mitral atresia.
Medical Definition
Mitral atresia is characterized by the complete absence of the mitral valve, leading to obstruction of blood flow from the left atrium to the left ventricle. Pathologically, there is a lack of valve tissue, and the left atrium may be hypoplastic. Histologically, the absence of normal valve structures is noted, with potential fibrous tissue in place of the valve. It is classified under congenital heart defects and is often associated with other cardiac anomalies. Epidemiologically, it is a rare condition with an incidence of approximately 1 in 100,000 live births. The disease course can vary, with some individuals requiring surgical intervention shortly after birth to ensure adequate blood circulation and oxygenation.
Mitral atresia Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Cyanosis manifests as a bluish discoloration of the skin and mucous membranes due to low oxygen levels in the blood. This occurs because mitral atresia impairs blood flow from the left atrium to the left ventricle, reducing oxygenated blood circulation. Over time, cyanosis can worsen as the heart struggles to compensate for the impaired blood flow. It affects daily life by causing fatigue and shortness of breath, and supplemental oxygen or surgical interventions may be necessary.
Shortness of breath occurs as the heart's ability to pump oxygenated blood is compromised. The biological mechanism involves increased pressure in the pulmonary circulation due to obstructed blood flow, leading to pulmonary congestion. This symptom can progressively worsen, especially during physical activities. Patients may need to limit exertion and use medications or surgical options to manage the condition.
Failure to thrive is characterized by inadequate weight gain and growth in infants. It results from the heart's inability to efficiently circulate oxygenated blood, affecting overall metabolism and energy levels. Over time, this can lead to developmental delays and poor physical growth. Nutritional support and medical management are crucial to improve growth outcomes and quality of life.
Common
Fatigue presents as a persistent feeling of tiredness and lack of energy. It is caused by the heart's reduced capacity to deliver sufficient oxygen to tissues, leading to decreased physical endurance. As the condition progresses, fatigue may become more pronounced, limiting daily activities. Management includes lifestyle adjustments, medications, and potentially surgical interventions to improve cardiac function.
A heart murmur is an abnormal sound heard during a heartbeat, often detected during a physical examination. It occurs due to turbulent blood flow across the heart's chambers and valves, which is common in structural heart defects like mitral atresia. The intensity and characteristics of the murmur can change over time as the heart condition evolves. Regular monitoring and echocardiograms are used to assess the murmur and guide treatment decisions.
Tachypnea is an abnormally rapid breathing rate. It results from the body's attempt to compensate for reduced oxygen levels in the blood by increasing respiratory rate. This symptom can become more severe with disease progression, especially during physical exertion or stress. Management may involve oxygen therapy and medications to support respiratory function.
Less Common
Edema is the swelling of tissues due to fluid accumulation, often seen in the lower extremities. It is caused by increased pressure in the venous system and fluid retention as the heart struggles to maintain efficient circulation. Over time, edema can lead to discomfort and mobility issues. Diuretics and other medications are often used to manage fluid balance and reduce swelling.
Palpitations are sensations of a rapid or irregular heartbeat. They occur due to abnormal electrical activity in the heart, which can be exacerbated by structural defects like mitral atresia. These sensations may become more frequent or intense over time, causing anxiety and discomfort. Treatment may include medications to regulate heart rhythm and lifestyle modifications to reduce triggers.
What Causes Mitral atresia?
Mitral atresia is primarily associated with genetic mutations affecting the NKX2-5 gene located on chromosome 5q34, which encodes a homeobox-containing transcription factor crucial for heart development. The NKX2-5 protein normally regulates the expression of other genes essential for cardiac morphogenesis and the formation of the atrioventricular valves. Mutations in NKX2-5 can lead to a truncated or misfolded protein, impairing its ability to bind DNA and activate target genes. This disruption in gene regulation results in the failure of proper mitral valve formation during embryonic development. Consequently, the absence of a functional mitral valve leads to altered hemodynamics and increased pressure in the left atrium, causing compensatory changes in the heart and lungs. The altered blood flow can trigger an inflammatory response, recruiting immune cells that exacerbate tissue remodeling and fibrosis. Over time, the persistent pressure overload and inflammation can lead to ventricular hypertrophy and pulmonary vascular changes. Neuroinflammation is not a primary feature of mitral atresia, but systemic hypoxia can affect neurological development. White matter degeneration is not directly implicated, but chronic hypoxemia might contribute to subtle neurodevelopmental delays. Symptoms typically appear shortly after birth due to the immediate hemodynamic consequences of the defect, such as cyanosis and heart failure. The severity of mitral atresia can vary based on the presence of additional cardiac anomalies, such as ventricular septal defects or coarctation of the aorta. Genetic modifiers and environmental factors during gestation may also influence disease severity and presentation. Understanding the genetic basis of mitral atresia helps in predicting outcomes and tailoring interventions for affected individuals.
How is Mitral atresia Diagnosed?
Typical age of diagnosis: Mitral atresia is typically diagnosed in infancy, often within the first few weeks of life, due to the presentation of symptoms such as cyanosis or heart failure. Diagnosis may occur during prenatal ultrasounds if severe cardiac anomalies are detected. Postnatal diagnosis is prompted by clinical signs and symptoms, leading to further investigation. Early diagnosis is crucial for timely intervention and management.
Clinicians look for signs of heart failure, cyanosis, and failure to thrive in infants. A detailed history of maternal health and any prenatal findings is important. Physical examination may reveal a heart murmur, tachypnea, and hepatomegaly. This step helps determine the urgency of further diagnostic testing and potential interventions.
Echocardiography is the primary imaging modality used to diagnose mitral atresia. It reveals the absence of the mitral valve and associated cardiac anomalies such as hypoplastic left heart syndrome. Findings on echocardiography confirm the diagnosis and help exclude other congenital heart defects. Cardiac MRI may be used for detailed anatomical assessment and surgical planning.
Blood tests including arterial blood gases and complete blood count are ordered. Biomarkers such as elevated lactate levels may indicate poor perfusion. Abnormal results guide the urgency of intervention and help assess the severity of the condition. These tests also assist in monitoring the patient's response to treatment.
Genetic testing may involve sequencing genes associated with congenital heart defects, such as NKX2-5 or GATA4. Mutations in these genes can be identified, confirming a genetic basis for the condition. Results can confirm the diagnosis and provide information for family counseling regarding recurrence risks. Genetic counseling is essential for family planning and understanding the hereditary nature of the condition.
Mitral atresia Treatment Options
Prostaglandin E1 is used to maintain ductal patency in neonates with mitral atresia. It works by dilating the ductus arteriosus, ensuring adequate systemic blood flow. Specific drugs include Alprostadil, which has shown efficacy in stabilizing patients preoperatively. Clinical evidence supports its use in improving oxygenation and delaying surgical intervention. Side effects may include apnea and hypotension, requiring careful monitoring.
Techniques include breathing exercises and monitored physical activity to improve cardiovascular function. The goal is to enhance exercise tolerance and respiratory efficiency. Sessions are typically conducted several times a week, with duration tailored to the patient's condition. Measurable outcomes include improved oxygen saturation and exercise capacity. Long-term benefits include enhanced quality of life and reduced hospitalizations.
Surgery is indicated for severe cases with compromised systemic circulation. The Norwood procedure involves reconstructing the aorta and creating a new pathway for blood flow. Expected benefits include improved systemic perfusion and oxygenation. Surgical risks include bleeding, infection, and arrhythmias. Post-operative care requires intensive monitoring and management of potential complications.
The care team includes cardiologists, surgeons, nurses, and social workers. Interventions focus on optimizing medical management and supporting developmental needs. Psychosocial support strategies address the emotional and mental health of the patient and family. Family education involves teaching about the condition, treatment options, and home care requirements. Long-term monitoring includes regular follow-up visits and echocardiograms to assess cardiac function.
When to See a Doctor for Mitral atresia
- Severe cyanosis — this indicates a critical lack of oxygen in the blood and requires immediate medical attention.
- Difficulty breathing — this can signify heart failure or severe pulmonary issues, necessitating emergency care.
- Loss of consciousness — this could be a sign of inadequate blood flow to the brain and is a medical emergency.
- Frequent respiratory infections — this may indicate compromised heart function and should be evaluated by a doctor.
- Poor feeding or failure to thrive in infants — this suggests potential heart failure or inadequate oxygenation, requiring medical assessment.
- Persistent fatigue — this can be a sign of heart strain and should prompt a consultation with a healthcare provider.
- Mild shortness of breath during exertion — monitor for worsening symptoms and consult a doctor if it progresses.
- Occasional palpitations — keep track of frequency and duration, and discuss with a healthcare provider if they become more frequent.
Mitral atresia — Frequently Asked Questions
Is this condition hereditary?
Mitral atresia is generally not considered hereditary, as it often occurs sporadically with no clear inheritance pattern. The probability of passing it to children is low, but genetic factors may play a role in some cases. De novo mutations can occur, meaning the condition arises without a family history. Carrier status is not typically applicable, as it is not a recessive genetic disorder. Genetic counseling is recommended for families with a history of congenital heart defects to understand potential risks.
What is the life expectancy for someone with this condition?
Life expectancy varies significantly depending on the severity of the condition and the presence of other congenital heart defects. Early intervention and surgical treatment can improve outcomes and extend survival. Mortality is often related to heart failure or complications from associated cardiac anomalies. Treatment, including surgical procedures, can enhance quality of life and increase lifespan. Realistic expectations should include ongoing medical care and potential limitations in physical activities.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis typically involves echocardiography, which visualizes the heart's structure and function. The time from first symptoms to diagnosis can vary, but it is often identified in infancy due to severe symptoms. Pediatric cardiologists are usually consulted for diagnosis and management. Delayed diagnosis may occur if symptoms are mild or atypical. Confirmation is achieved through imaging studies and sometimes cardiac catheterization.
Are there any new treatments or clinical trials available?
Current research is exploring advanced surgical techniques and potential gene therapies to improve outcomes. Novel approaches such as tissue engineering for valve replacement are being investigated. Clinical trials can be found on ClinicalTrials.gov by searching for mitral atresia or congenital heart defects. Patients should ask their doctors about eligibility for trials and potential benefits. New treatments may take several years to become widely available, depending on trial results and regulatory approvals.
How does this condition affect daily life and activities?
Mitral atresia can significantly impact mobility and self-care, especially in severe cases. Educational implications may include the need for special accommodations due to fatigue or medical appointments. Social and emotional challenges arise from physical limitations and the need for frequent medical care. Family burden includes managing complex care needs and potential financial strain. Supports such as cardiac rehabilitation, counseling, and educational resources can help improve quality of life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Mitral Atresia with Normal Aortic Root.
Rao PS · Children (Basel) · 2022 · PMID: 36010040
- 2.The clinical morphology of mitral atresia. Atresia of the left atrioventricular valve.
Anderson RH, Thiene G · G Ital Cardiol · 1981 · PMID: 7049816
- 3.[Mitral atresia with ventricular septal defect].
Hoshino S, Tanji M · Ryoikibetsu Shokogun Shirizu · 1996 · PMID: 9117588
- 4.[Mitral stenosis, mitral atresia and mitral insufficiency].
Ohkubo M, Ino T, Okada R · Ryoikibetsu Shokogun Shirizu · 1996 · PMID: 9117607
- 5.Mitral atresia.
Molina JE · J Thorac Cardiovasc Surg · 1979 · PMID: 502578
- 6.Mitral atresia.
Szarnicki RJ · J Thorac Cardiovasc Surg · 1979 · PMID: 502577
- 7.Congenital mitral atresia.
TELLER WM · Am Heart J · 1958 · PMID: 13545179
- 8.Mitral atresia. Morphological details.
Gittenberger-de Groot AC, Wenink AC · Br Heart J · 1984 · PMID: 6696802
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-05-26